ICH guideline E2F on development safety update …
September 2011 . EMA/CHMP/ICH/309348/2008 . ICH guideline E2F on development safety update report . Step 5 . Transmission to CHMP
Download ICH guideline E2F on development safety update …
Information
Domain:
Source:
Link to this page:
Documents from same domain
Q12 Step 2b Technical and regulatory …
www.ema.europa.euICH guideline Q12 on technical and regulatory considerations for pharmaceutical product lifecycle management EMA/CHMP/ICH/804273/2017 Page 3/36
Guideline on good pharmacovigilance practices …
www.ema.europa.eu9 December 2013 . EMA/816292/2011 Rev 1* Guideline on good pharmacovigilance practices (GVP) Module VII – Periodic safety update report (Rev 1)
Guideline on good pharmacovigilance practices (GVP)
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module IX (Rev 1) EMA/827661/2011 Rev 1 Page 2/25
Guideline on good pharmacovigilance practices …
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module VIII (Rev 3) EMA/813938/2011 Rev 3 Page 2/28
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/70 Document History First Codification History Date New Codification
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/75 10 Document History 11 First Codification History Date New Codification November
Guideline on good pharmacovigilance practices …
www.ema.europa.euharmful physical or psychological effects [DIR 2001/83/EC Art 1(1 6)]. 74 Adverse event (AE); synonym: Adverse experience 75 Any untoward medical occurrence in a patient or clinical- trial subject administered a medicinal product
European Medicines Agency
www.ema.europa.eu© EMEA 2006 2 SPECIFICATIONS: TEST PROCEDURES AND ACCEPTANCE CRITERIA FOR BIOTECHNOLOGICAL/BIOLOGICAL PRODUCTS ICH Harmonised Tripartite Guideline
products1/traditional herbal medicinal products
www.ema.europa.euThere is no expectation that existing herbal medicinal products on the market will be affected by this guideline, with the exception of traditional herbal medicinal products for human use that were already
Q7 Q&A - good manufacturing practice for active ...
www.ema.europa.euICH guideline Q7 on good manufacturing practice for active pharmaceutical ingredients – questions and answers EMA/CHMP/ICH/468930/2015 Page 2/37
Related documents
Manual tasks audit guide - Department of Mines, …
www.dmp.wa.gov.auManual tasks audit – guide Page 2 of 16 Introduction This document was reformatted in November 2015. At this time no material changes were made to the
CVMP Recommendation on Assessment of Periodic …
www.ema.europa.euemea/cvmp/phvwp/4550/2006 page 2 of 20 recommendation on management and assessment of periodic safety update reports (psurs) of veterinary medicinal products
Overview of ICH E2F – Development …
www.ich.orgOverview of ICH E2F – Development SafetyDevelopment Safety Update Report (DSUR) International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use
DEVELOPMENT SAFETY UPDATE REPORT - ICH
www.ich.orginternational conference on harmonisation of technical requirements for registration of pharmaceuticals for human use . ich harmonised tripartite guideline. development safety update report
Gender, Climate Change and Health - WHO | World …
www.who.intand Health (GWH) and the Department of Public Health and Environment (PHE) of the World Health Organization (WHO) to systematically address gender equality in …
Efavirenz Safety Review - WHO
www.who.int5 The most recent antiretroviral pregnancy registry received prospective reports on 620 pregnancies exposed to EFV-containing regimens, a majority of which were first-
Full Prescribing Information - NERLYNX
nerlynx.com2.3 Dose Modifications Dose Modifications for Adverse Reactions NERLYNX dose modification is recommended based on individual safety and tolerability.
What Is a Safety Signal? - Pfizer
www.pfizer.comWhat Is a Safety Signal? (cont’d) All spontaneous reports received by the FDA are entered into the Adverse Event Reporting System (AERS), a database designed to support the FDA’s post-approval safety surveillance
Related search queries
Manual tasks audit guide, Manual tasks audit – guide, Assessment of Periodic, Assessment of periodic safety, Reports, E2F – Development SafetyDevelopment Safety Update Report, Development safety update report, Health, World Health Organization, Efavirenz Safety Review, Prescribing Information, Safety, Pfizer